» Articles » PMID: 15322517

The Search for Low-penetrance Cancer Susceptibility Alleles

Overview
Journal Oncogene
Date 2004 Aug 24
PMID 15322517
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Much of the familial aggregation of common cancer results from inherited susceptibility, but highly penetrant mutations in known genes cannot account for most of the excess. Some of the unexplained familial risk is presumably due to high-penetrance mutations in as yet unidentified genes, but polygenic mechanisms are likely to account for a greater proportion, particularly in breast cancer. This inference, coupled with technological developments, has led to a renaissance in association studies. Most such studies have evaluated small numbers of single-nucleotide polymorphisms (SNPs) in a few candidate genes, but reliable high-density oligonucleotide arrays and other novel techniques will allow genome-wide allelic association studies to be conducted. High-density genome-wide SNP analysis will include targets identified by structural considerations, as well as the growing list of candidate genes. In the longer term, high-throughput re-sequencing will be required to identify the rare pathogenic variants that may constitute the majority of low-penetrance alleles. The detection of low-penetrance cancer susceptibility genes will then be restricted mainly by the availability of large numbers of well-characterized cases and controls. Cancer patients with affected relatives are considerably more informative than unselected cases for such studies.

Citing Articles

Identifying polymorphic cis-regulatory variants as risk markers for lung carcinogenesis and chemotherapy responses in tobacco smokers from eastern India.

Sengupta D, Mukhopadhyay P, Banerjee S, Ganguly K, Mascharak P, Mukherjee N Sci Rep. 2023; 13(1):4019.

PMID: 36899086 PMC: 10006236. DOI: 10.1038/s41598-023-30962-9.


Gene polymorphisms and risk of head and neck squamous cell carcinoma: a systematic review.

Rajabi-Moghaddam M, Abbaszadeh H Rep Pract Oncol Radiother. 2023; 27(6):1058-1076.

PMID: 36632298 PMC: 9826653. DOI: 10.5603/RPOR.a2022.0115.


Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis.

Pudjihartono M, Perry J, Print C, OSullivan J, Schierding W Clin Epigenetics. 2022; 14(1):120.

PMID: 36171609 PMC: 9520844. DOI: 10.1186/s13148-022-01342-3.


Structural insights and evaluation of the potential impact of missense variants on the interactions of SLIT2 with ROBO1/4 in cancer progression.

Sengupta D, Bhattacharya G, Ganguli S, Sengupta M Sci Rep. 2020; 10(1):21909.

PMID: 33318575 PMC: 7736846. DOI: 10.1038/s41598-020-78882-2.


Mapping of new skin tumor susceptibility loci by a phenotype-driven congenic approach.

Fujiwara K, Inagaki Y, Soma M, Ozaki T, Nagase H Oncol Lett. 2018; 16(5):6670-6676.

PMID: 30405807 PMC: 6202554. DOI: 10.3892/ol.2018.9495.